TITLE:
The Efficacy of Ferumoxytol in Peritoneal Dialysis Patients: A Short Scientific Report
AUTHORS:
Sayed Husain, Hani Judeh, Manaf Alroumoh, Farhana Yousaf, Prince Mohan, Ahla Husain, Chaim Charytan, Bruce Spinowitz
KEYWORDS:
Anemia, Ferumoxytol, Peritoneal Dialysis
JOURNAL NAME:
Open Journal of Nephrology,
Vol.4 No.2,
June
25,
2014
ABSTRACT:
One of the major
elements contributing to anemia in Chronic Kidney Disease (CKD) patients is
iron deficiency. Iron supplementation in oral form is often not tolerated and
ineffectively absorbed. Intravenous (IV) infusion is time consuming and is
inconvenient in Peritoneal Dialysis (PD) patients self-treating at home. A new
preparation of iron, ferumoxytol, is a carbohydrate-coated, paramagnetic iron
oxide nanoparticle, which can be administered as a bolus intravenous injection,
allowing the PD patient to more easily comply with current IV iron dosing
regimens. Few studies have been done to evaluate the efficacy of ferumoxytol in
PD population. We retrospectively reviewed the medical records of peritoneal
dialysis patients who received at least one dose of ferumoxytol between January
2010 and August 2010 and observed that 17 patients showed an improvement in
hemoglobin (Hb) to 1 gm/dl within a month of treatment along with a decrease in
epoetin dosage in subsequent weeks.